Project Grant HT94252510688
Award Date
7/15/25
Completion Date
7/14/27
Dollars Obligated
$606K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21218, USA
Similar Awards
The Johns Hopkins University will receive $654,998 through a Project Grant award from the Defense Health Agency to support research targeting regulatory B cells to augment anti-bladder cancer immunity. The grant was awarded on June 1, 2023 under the Military Medical Research and Development program (CFDA 12.420), with work expected to be completed by May 31, 2026 in Baltimore, Maryland. Through this funding, The Johns Hopkins University will conduct research aimed at transforming healthcare...
The Johns Hopkins University was awarded a $974,999.00 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The three-year grant, spanning August 1, 2023 to July 31, 2026, will support research to engineer an effective combination therapy of car T cells and regulatory T cells to control rejection of vascularized composite allografts. This research aims to develop medical solutions for the battlefield and transform healthcare for...
The Johns Hopkins University was awarded a $1,228,125 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will support research titled "PSMA-TARGETED ACTIVATED MYELOID CELLS AS A NOVEL PROSTATE CANCER IMMUNOTHERAPY" from September 2021 through September 2024. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical...
The U.S. Defense Health Agency has awarded a $655,000 Project Grant to The Johns Hopkins University under the Military Medical Research and Development (CFDA 12.420) program. The grant, which runs from September 1, 2024 to August 31, 2028, supports research to identify and circumvent resistance after donor-derived ex vivo expanded natural killer (NK) cells and haploidentical hematopoietic cell transplantation (haplo-HCT) in children and young adults with high-risk acute myeloid leukemia (AML)....
The U.S. Defense Health Agency awarded a $776,831 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to The Johns Hopkins University to conduct research on P2 purinergic receptors in pancreatic ductal adenocarcinoma as potential therapeutic targets. The grant, which runs from August 1, 2025 to July 31, 2028, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. As a leading...
This $867,712 Project Grant award from the Department of the Army Medical Command (under the Military Medical Research and Development program, CFDA 12.420) supports advanced biomedical research at The Johns Hopkins University focused on transforming healthcare for military service members and the general public. The research aims to investigate effective treatment of pancreatic cancer through systemic chemotherapy combined with alpha-particle radiotherapy, with a focus on early hepatic...
This $1,473,750 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports The Johns Hopkins University's research study on "The Immunomodulatory Impact of Chemotherapy When Combined with PD-1 Blockade in Resectable Lung Cancer." The 3-year grant, running from September 1, 2024 to August 31, 2027, aims to investigate innovative immunological interventions for treating lung cancer in military service...
The Department of Defense's Defense Health Agency awarded a $232,878 Project Grant to The Johns Hopkins University to conduct research on "EXPLORING THE ROLE OF EPITRANSCRIPTOMICS IN THE EVOLUTION OF NEUROENDOCRINE PROSTATE CANCER." This grant is funded through the Military Medical Research and Development (CFDA 12.420) program, which supports advanced biomedical research to transform healthcare for military service members, veterans, and the public. The research will be conducted from...
The Johns Hopkins University was awarded a $1,170,746 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to investigate the polyaneuploid cancer cell state and its role in mediating multitherapy resistance in cancer. The three-year award, effective August 15, 2022 through August 14, 2025, will support research into transforming healthcare for service members and the public through innovative biomedical...
The Johns Hopkins University received a $722,589.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on localized and inflammation-responsive immunotherapy of vascular composite allograft (VCA) rejection. The 3-year project, which commenced on July 1, 2023 and is slated for completion by June 30, 2026, aims to transform healthcare for service members and the American public by investigating innovative...